Actuate Therapeutics

As of March 31, 2026, cash and equivalents were 8.1 million dollars with a disclosed runway only into July 2026 and a stated going‑concern warning. TTM net cash used in operations is approximately 19.6 million dollars (2025 operating cash outflow of 19.2 million plus Q1‑26 outflow of 5.0 million minus Q1‑25 outflow of 4.6 million).

The firm relies on an ATM facility up to 100 million dollars and a 50 million‑dollar committed equity facility, signaling likely dilution. Balance sheet liabilities are modest (notably a UIC license payable), but financing risk is high.